New RxSight CEO's 2.31M RSU award vests over three years
RxSight (NASDAQ: RXST) said it granted new CEO Aziz Mottiwala inducement equity awards on July 24, 2026. The package includes stock options for 571,286 shares with a $5.19 exercise price and RSUs for 2,312,138 shares. Options vest 25% at one year then monthly, while RSUs vest 20%, 20%, then 60% over three years.
How this was made
The 30-second read
Why it matters
Traders may reassess medium-term dilution/overhang and the timing of stock-based compensation expense, but the article does not change operating outlook or introduce new clinical or commercial milestones.
Market read
A completed CEO inducement grant with large share counts and staged vesting can affect dilution expectations, but lacks new financial guidance or operational catalysts.
What to watch
Option exercise at $5.19 (equal to grant-date close) means dilution depends on future stock performance; if the stock underperforms, fewer options may be exercised, reducing realized dilution.
Background
RxSight announced inducement equity awards to its newly hired CEO, governed by Nasdaq Listing Rule 5635(c)(4) and the 2026 Inducement Equity Incentive Plan.
Ticker impact
RxSight granted CEO Aziz Mottiwala inducement options for 571,286 shares at $5.19 and RSUs for 2,312,138 shares, with multi-year vesting.
Near-term impact likely limited; any reaction would be sentiment-driven around dilution and CEO alignment rather than fundamentals.
The article provides exact grant sizes, exercise price, and vesting schedule, which informs dilution/overhang and compensation expense timing. However, it does not include new guidance, trial/product outcomes, or financing terms that would directly reset valuation.
Market effects
For ophthalmic medical device peers, large inducement equity grants can signal competitive executive retention needs, but this is company-specific rather than a sector reset.
No clear regional macro linkage; impact is primarily issuer-specific.
Limited global relevance; the event is a US-listed company’s internal compensation arrangement.
Counterpoint
The vesting is back-ended (RSUs mostly vest at year 3), so near-term dilution pressure may be overstated versus the longer-dated alignment benefit.
Key entities
- companyRxSight, Inc.
NASDAQ-listed ophthalmic medical device company that granted inducement stock options and RSUs to its new CEO.
- personAziz Mottiwala
New President and Chief Executive Officer receiving inducement equity awards.
- program2026 Inducement Equity Incentive Plan
Equity plan under which the inducement awards were granted, referenced alongside Nasdaq Rule 5635(c)(4).
